NVS  Novartis Ag




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

+0.16 (+0.17%)

Growth Price

Overvalued by 33.58%

Stability Price

Overvalued by 77.35%

Company Metrics

  • P/E 12.04
  • P/S 4.46
  • P/B 2.93
  • EPS 7.96
  • Cash ROIC 12.42%
  • Cash Ratio 0.51
  • Dividend 2.67 / 2.82%
  • Avg. Vol. 1.86M
  • Shares 2.42B
  • Market Cap. 231.28B

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Here's How Novartis AG Biosimilar Launch Could Affect Amgen, Inc.
Bidness ETC - 17 hours ago
September 3 would mark the launch of the first biosimilar in U.S., as Novartis AG ADR (NYSE:NVS) is gearing up to launch Zarxio, the biosimilar version of Amgen Inc.'s (NASDAQ:AMGN) cancer drug Neupogen.
Novartis AG (ADR) (NYSE:NVS) Triumphs against Amgen, Inc. (NASDAQ:AMGN) - WallStreet Scope
Novartis AG (ADR) Partners With Amgen, Inc. On Alzheimer's And Migraine
Bidness ETC - Sep 2, 2015
Amgen, Inc. (NASDAQ:AMGN) entered into a two-way partnership deal with Novartis AG (ADR) (NYSE:NVS) on Tuesday, to co-develop the Swiss drug-maker's Alzheimer's drug pipeline, in exchange for Novartis gaining access to Amgen's migraine drug ...
Novartis AG (ADR) (NYSE:NVS) Revolade Gets EU Nod
Wall Street Observer - Sep 2, 2015
Novartis AG (ADR) (NYSE:NVS) the oncology drug maker is now all set to market key Severe Aplastic Anemia (SAA) drug, Revolade in Europe soon.
Novartis AG (ADR) (NVS) Stock Update: Decline Driven By Forex Headwinds
Bidness ETC - Aug 24, 2015
Novartis AG (ADR) (NYSE:NVS) stock has registered a decline of 6.06% over the past three months, aided in large part by the global market chaos that's bogging down the entire healthcare sector's stock performance.
News Recap - Novartis (NVS), China Mobile (CHL), Facebook (FB), General ... - Techsonian (press release)
Novartis AG (ADR) (NVS) To Acquire Spinifex
Business Finance News - Jun 29, 2015
Novartis AG (ADR) (NYSE:NVS) has announced the acquisition of Spinifex Pharmaceuticals, Inc. The acquisition will allow Novartis to gain access to Spinifex's experimental drugs for chronic pain.
Novartis AG (ADR) (NVS) To Acquire Spinifex For $200 Million - Bidness ETC
Novartis to buy privately held Spinifex for $200 mln - Proactive Investors USA & Canada
Will Novartis AG (ADR) Buy Pfizer Inc. Biosimilar Remicade?
Bidness ETC - Aug 6, 2015
Pfizer Inc. (NYSE:PFE) nears the completion of its $16 billion acquisition of Hospira Inc. (NYSE:HSP). The deal, which was agreed upon by the two parties in February, secured approval from the European regulators earlier this week, and now awaits ...
GlaxoSmithKline plc Deal Unlikely To Help Novartis AG Top Oncology Sales
Bidness ETC - Aug 17, 2015
Novartis AG (ADR) (NYSE:NVS) concluded its three-way asset swap transaction with GlaxoSmithKline plc. (ADR) (NYSE:GSK) in March 2015.
Stock Report on Novartis AG (ADR) (NYSE:NVS)
Street Report - Jun 16, 2015
[CNW Group] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) announced one-year study results from the MEASURE 2 pivotal Phase III study of investigational secukinumab in ankylosing spondylitis (AS).
Novartis AG (NVS) Stock Soars On Heart-Failure Drug Approval
Bidness ETC - Jul 8, 2015
The US Food and Drug Administration (FDA) has approved Novartis AG's (ADR) (NYSE:NVS) new heart-failure drug, Entresto, the agency announced in a press release on Tuesday.
Novartis' Heart Failure Drug Entresto Receives FDA Approval - Analyst Blog - Nasdaq
Novartis Heart Failure Drug Entresto Receives FDA Approval - Zacks.com
Novartis AG (ADR) Declines As Merck andamp; Co., Wins Patent Battle
Bidness ETC - Aug 21, 2015
Novartis AG ADR (NYSE:NVS) declined 2.3% during yesterday's trade as the company lost a patent battle to Merck & Co.